Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET
Company Participants
Clint Tomlinson - Investor Relations
Christopher Missling - President and CEO
Sandra Boenisch - Principal Financial Officer
Conference Call Participants
Tom Bishop - BI Research
Soumit Roy - Jones Research
Clint Tomlinson
Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions]. Please note this conference is being recorded, and the call will be available for replay on Anavex's website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations, and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC. This includes without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.
These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights.
And with that, I'd like to turn the call over to Dr. Missling.
Christopher Missling
Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive results from the Phase 2b/3 clinical trial, blarcamesine, ANAVEX®2-73, which represented at the Alzheimer's Association International Conference AAIC, showing that oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease, patients with good comparative safety profile and/or associated neuroimaging adverse events.
Full data from the blarcamesine study in Alzheimer's disease Phase 2b/3 placebo controlled clinical trial will be published in an upcoming peer-reviewed journal. The initiated process for submitting a Marketing Authorization application, MAA, to the European Medicine Agency, EMA, under the Centralized Procedure is underway with full regulatory submission of blarcamesine expected in Q4 of 2024.